Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 26;7(11):389.
doi: 10.3390/jcm7110389.

Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE-MTDPS1)

Affiliations
Review

Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE-MTDPS1)

Massimiliano Filosto et al. J Clin Med. .

Abstract

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE-MTDPS1) is a devastating autosomal recessive disorder due to mutations in TYMP, which cause a loss of function of thymidine phosphorylase (TP), nucleoside accumulation in plasma and tissues, and mitochondrial dysfunction. The clinical picture includes progressive gastrointestinal dysmotility, cachexia, ptosis and ophthalmoparesis, peripheral neuropathy, and diffuse leukoencephalopathy, which usually lead to death in early adulthood. Other two MNGIE-type phenotypes have been described so far, which are linked to mutations in POLG and RRM2B genes. Therapeutic options are currently available in clinical practice (allogeneic hematopoietic stem cell transplantation and carrier erythrocyte entrapped thymidine phosphorylase therapy) and newer, promising therapies are expected in the near future. Since successful treatment is strictly related to early diagnosis, it is essential that clinicians be warned about the clinical features and diagnostic procedures useful to suspect diagnosis of MNGIE-MTDPS1. The aim of this review is to promote the knowledge of the disease as well as the involved mechanisms and the diagnostic processes in order to reach an early diagnosis.

Keywords: MNGIE; MTDPS1; mitochondrial diseases; mitochondrial neurogastrointestinal encephalopathy; mitochondrial therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Axial (A) and sagittal (B) brain MRI (magnetic resonance imaging) view shows marked leukoencephalopathy in a MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy) subject.

Similar articles

Cited by

References

    1. Nishino I., Spinazzola A., Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 1999;283:689–692. doi: 10.1126/science.283.5402.689. - DOI - PubMed
    1. Viscomi C., Zeviani M. mMtDNA-maintenance defects: Syndromes and genes. J. Inherit. Metab. Dis. 2017;40:587–599. doi: 10.1007/s10545-017-0027-5. - DOI - PMC - PubMed
    1. El-Hattab A.W., Scaglia F. SUCLA2-Related Mitochondrial DNA Depletion Syndrome, Encephalomyopathic form with Methylmalonic Aciduria. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J.H., Stephens K., Amemiya A., editors. GeneReviews®. University of Washington; Seattle, WA, USA: 1993–2018. - PubMed
    1. Nishino I., Spinazzola A., Papadimitriou A., Hammans S., Steiner I., Hahn C.D., Connolly A.M., Verloes A., Guimarães J., Maillard I., et al. Mitochondrial neurogastrointestinal encephalomyopathy: An autosomal recessive disorder due to thymidine phosphorylase mutations. Ann. Neurol. 2000;47:792–800. doi: 10.1002/1531-8249(200006)47:6<792::AID-ANA12>3.0.CO;2-Y. - DOI - PubMed
    1. Spinazzola A., Marti R., Nishino I., Andreu A.L., Naini A., Tadesse S., Pela I., Zammarchi E., Donati M.A., Oliver J.A., et al. Altered thymidine metabolism due to defects of thymidine phosphorylase. J. Biol. Chem. 2002;277:4128–4133. doi: 10.1074/jbc.M111028200. - DOI - PubMed

LinkOut - more resources